200 related articles for article (PubMed ID: 20688444)
1. Role and limitations of 18F-FDG positron emission tomography (PET) in the management of patients with pancreatic lesions.
Pery C; Meurette G; Ansquer C; Frampas E; Regenet N
Gastroenterol Clin Biol; 2010 Sep; 34(8-9):465-74. PubMed ID: 20688444
[TBL] [Abstract][Full Text] [Related]
2. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
[TBL] [Abstract][Full Text] [Related]
3. Impact of F18-fluorodeoxyglycose positron emission tomography/computed tomography on the management of resectable pancreatic tumours.
Yao J; Gan G; Farlow D; Laurence JM; Hollands M; Richardson A; Pleass HC; Lam VW
ANZ J Surg; 2012 Mar; 82(3):140-4. PubMed ID: 22510123
[TBL] [Abstract][Full Text] [Related]
4. Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions?
Casneuf V; Delrue L; Kelles A; Van Damme N; Van Huysse J; Berrevoet F; De Vos M; Duyck P; Peeters M
Acta Gastroenterol Belg; 2007; 70(4):331-8. PubMed ID: 18330088
[TBL] [Abstract][Full Text] [Related]
5. Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma.
Delbeke D; Rose DM; Chapman WC; Pinson CW; Wright JK; Beauchamp RD; Shyr Y; Leach SD
J Nucl Med; 1999 Nov; 40(11):1784-91. PubMed ID: 10565771
[TBL] [Abstract][Full Text] [Related]
6. ¹⁸F-FDG PET/CT imaging of the pancreas: spectrum of diseases.
Nguyen VX; Nguyen CC; Nguyen BD
JOP; 2011 Nov; 12(6):557-66. PubMed ID: 22072244
[TBL] [Abstract][Full Text] [Related]
7. 2-(fluorine-18)-fluoro-2-deoxy-D-glucose PET in detection of pancreatic cancer: value of quantitative image interpretation.
Stollfuss JC; Glatting G; Friess H; Kocher F; Berger HG; Reske SN
Radiology; 1995 May; 195(2):339-44. PubMed ID: 7724750
[TBL] [Abstract][Full Text] [Related]
8. 18-fluorodeoxyglucose positron emission tomography enhances computed tomography diagnosis of malignant intraductal papillary mucinous neoplasms of the pancreas.
Sperti C; Bissoli S; Pasquali C; Frison L; Liessi G; Chierichetti F; Pedrazzoli S
Ann Surg; 2007 Dec; 246(6):932-7; discussion 937-9. PubMed ID: 18043094
[TBL] [Abstract][Full Text] [Related]
9. F-18 fluorodeoxyglucose PET in vivo evaluation of pancreatic glucose metabolism for detection of pancreatic cancer.
Bares R; Klever P; Hauptmann S; Hellwig D; Fass J; Cremerius U; Schumpelick V; Mittermayer C; Büll U
Radiology; 1994 Jul; 192(1):79-86. PubMed ID: 8208970
[TBL] [Abstract][Full Text] [Related]
10. The clinical usefulness of 18-fluorodeoxyglucose positron emission tomography in the differential diagnosis, staging, and response evaluation after concurrent chemoradiotherapy for pancreatic cancer.
Bang S; Chung HW; Park SW; Chung JB; Yun M; Lee JD; Song SY
J Clin Gastroenterol; 2006; 40(10):923-9. PubMed ID: 17063113
[TBL] [Abstract][Full Text] [Related]
11. 18F-FDG positron emission tomography CT (FDG PET-CT) in the management of pancreatic cancer: initial experience in 12 patients.
Saif MW; Cornfeld D; Modarresifar H; Ojha B
J Gastrointestin Liver Dis; 2008 Jun; 17(2):173-8. PubMed ID: 18568138
[TBL] [Abstract][Full Text] [Related]
12. Nonfunctioning endocrine pancreatic tumor examined with 18F-FDG PET/CT.
Toshikuni N; Kai K; Fujisawa M
Ann Nucl Med; 2008 Feb; 22(2):133-7. PubMed ID: 18311538
[TBL] [Abstract][Full Text] [Related]
13. The role of positron emission tomography in the management of pancreatic cancer.
Pakzad F; Groves AM; Ell PJ
Semin Nucl Med; 2006 Jul; 36(3):248-56. PubMed ID: 16762614
[TBL] [Abstract][Full Text] [Related]
14. (18)F-FDG PET/CT can be used to detect non-functioning pancreatic neuroendocrine tumors.
Luo G; Liu Z; Guo M; Jin K; Xiao Z; Liu L; Xu J; Zhang B; Liu C; Huang D; Hu S; Ni Q; Long J; Yu X
Int J Oncol; 2014 Oct; 45(4):1531-6. PubMed ID: 25096059
[TBL] [Abstract][Full Text] [Related]
15. Preoperative evaluation of pancreatic masses with positron emission tomography using 18F-fluorodeoxyglucose: diagnostic limitations.
Sendler A; Avril N; Helmberger H; Stollfuss J; Weber W; Bengel F; Schwaiger M; Roder JD; Siewert JR
World J Surg; 2000 Sep; 24(9):1121-9. PubMed ID: 11036292
[TBL] [Abstract][Full Text] [Related]
16. PET/CT fusion scan enhances CT staging in patients with pancreatic neoplasms.
Farma JM; Santillan AA; Melis M; Walters J; Belinc D; Chen DT; Eikman EA; Malafa M
Ann Surg Oncol; 2008 Sep; 15(9):2465-71. PubMed ID: 18551347
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of pancreatic tumors with positron emission tomography and F-18 fluorodeoxyglucose: comparison with CT and US.
Inokuma T; Tamaki N; Torizuka T; Magata Y; Fujii M; Yonekura Y; Kajiyama T; Ohshio G; Imamura M; Konishi J
Radiology; 1995 May; 195(2):345-52. PubMed ID: 7724751
[TBL] [Abstract][Full Text] [Related]
18. [Results of positron emission tomography with fluorine-18 labeled fluorodeoxyglucose in differential diagnosis and staging of pancreatic carcinoma].
Bares R; Dohmen BM; Cremerius U; Fass J; Teusch M; Büll U
Radiologe; 1996 May; 36(5):435-40. PubMed ID: 8778929
[TBL] [Abstract][Full Text] [Related]
19. [The role of whole body 2-[fluorine-18]-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in the management of unknown primary tumors].
Wu ZJ; Zhang YX; Wei H; Jia Q
Zhonghua Yi Xue Za Zhi; 2007 Aug; 87(32):2253-6. PubMed ID: 18001544
[TBL] [Abstract][Full Text] [Related]
20. [The value of fluorodeoxyglucose positron emission tomography (FDG-PET) in differentiation of pancreatic lesions].
Voth M; Opfermann T; Gottschild D
Zentralbl Chir; 2003 May; 128(5):375-8. PubMed ID: 12813634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
